The relationship of diabetes mellitus and acute coronary syndrome in Bima Public Hospital: a cross sectional study

Nurfitriani ., Nurfathonah Aryana


Background: Diabetes Mellitus type II (DM) is one of risk factors of Acute Coronary Syndrome (ACS). Based on a study, hyperglycaemia can increase mortality in hospitalized patients due to ACS. Other studies also mention that there is significant relation between hyperglycaemia and incidence of ST elevation myocardial infarction (STEMI). Currently, data regarding the relationship between DM and ACS in Indonesia is still limited. The purpose of this study was to determine the relationship between the ACS and DM in inpatients at Bima public hospital, Indonesia.

Methods: This study was a cross sectional study. Data were obtained from medical records of inpatients at Bima public hospital in January 2020 to December 2020. The sample was selected by consecutive sampling. All 146 patient’s data that met inclusion criteria were analysed using chi-square test.

Results: The 146 patients which met inclusions criteria, as many as 85 people (58,2%) were male and 61 people (41,8%) were female. Based on age characteristics, 56 people (38,4%) were elderly and 90 people (61,6%) were adults. From 73 people diagnosed with ACS, there were 47 people (64,4%) diagnosed with DM and 26 people (35,5%) were not diagnosed with DM. Results of bivariate analysis, showed a significant relationship between DM and ACS with p value= 0.003 (OR = 2.743, 95% CI= 1.403-5.361).

Conclusions: Patients with DM are 2.7 times more likely to have ACS compared to non-DM. There is statistically significant relationship between DM and ACS.


Acute coronary syndrome, Diabetes mellitus, STEMI, NSTEMI, Unstable angina pectoris

Full Text:



Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745-9.

Deswal R, Narwal V, Dang A,Pundir CS. The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. J Hum Reprod Sci. 2020;13(4): 261-71.

Aversa A, Sandro LV, Rocco R, Alessandra G, Nappi RE, Calogero AE, et al. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Front Endocrinol. 2020;11:516.

Vignesh JP, Mohan V. Polycystic ovary syndrome: A component of metabolic syndrome? J Postgrad Med. 2007;53:128-34.

Legro RS. Polycystic ovary syndrome and cardiovascular disease: A premature association? Endocr Rev. 2003;24:302-12.

Grundy SM, Cleeman JL, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.

Teede HJ, Joham AE, Paul E, Moran LJ, Loxton D, Jolley DJ, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity. 2013;21:1526-32.

Lindberg S, Jensen JS, Bjerre M, Frystyk J, Flyvbjerg A, Jeppesen J, et al. Low adiponectin levels at baseline and decreasing adiponectin levels over 10 years of follow-up predict risk of the metabolic syndrome. Diabetes Metab. 2017;43:134-9.

Demirci H, Yilmaz M, Ergun MA, Yurtcu E, Bukan N, Ayvaz G. Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance and clinical parameters. Gynecol Endocrinol. 2010;26:348-55.

Shirazi FKH, Khodamoradi Z, Jeddi M. Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with polycystic ovarian syndrome (PCOS). BMC Endocr Disord. 2021;21:45.

Igwegbe AO, Eleje GU,Enechukwu CI. Polycystic Ovary Syndrome: A Review of Management Outcomes in a Low Resource Setting. J Women’s Health Issues Care. 2013;2:3.

Cochrane WG. Sampling techniques. 2nd ed. New York: John Wiley and Sons Inc; 1963.

Gowthami P, Kiranmayi VS, Rani BS, Suresh V,Vijayalakshmi DB. Study of serum adiponectin levels in women with polycystic ovary syndrome. Indian J Obstet Gynecol Res. 2019;6(3):288-92.

O'Connor A, Phelan N, Tun TK, BoranG, Gibney J, Roche HM. High molecular-Weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab. 2010;95(3):1378-85.

Wang T, Sha L, Li Y, Zhu L, Wang Z, Li K, et al. Plasma adiponectin levels and type 2 diabetes risk: a nested case-control study in a Chinese population and an updated meta-analysis. Sci Rep. 2018;8(1):406.

Zhang J, Xu JH, Qu QQ,Zhong GQ. Risk of Cardiovascular and Cerebrovascular Events in Polycystic Ovarian Syndrome Women: A Meta-Analysis of Cohort Studies. Front Cardiovasc Med. 2020;7:552421.

Al-Goblan AS, Al-Alfi MA, Khan, MZ. Mechanism linking diabetes mellitus and obesity. Diabet Metab Synd Obes Targets Ther. 2014;7:587-91.

Zhu JP, Teng YC, Zhou J, Lu W, Tao MF, Jia WP. Increased mean glucose levels in patients with polycystic ovary syndrome and hyperandrogenemia as determined by continuous glucose monitoring. Acta Obstet Gynecol Scand. 2013;92(2):165-71.

Veena HC, Reshmarani, Shilpa N. Altered blood glucose levels in polycystic ovary syndrome. Sch J Appl Med Sci. 2014;2(5F):1942-5.

Kheirollahi A, Teimouri M, Karimi M, Vatannejad A, Moradi N, Borumandnia N, et al. Evaluation of lipid ratios and triglyceride-glucose index as risk markers of insulin resistance in Iranian polycystic ovary syndrome women. Lipids Health Dis. 2020;19(1):235.

Rashidi H, Tafazoli M, Jalali MT, Mofrad AME. Serum lipid profile and insulin resistance in women with polycystic ovary syndrome (PCOS). J Diab Metab Disord Control. 2018;5(3):107-11.

Linder S, Abu-Omar K, Geidl W, Messing S, Sarshar M, Reimers AK, et al. Physical inactivity in healthy, obese, and diabetic adults in Germany: An analysis of related socio-demographic variables. PloS One. 2021;16(2):e0246634.

Ollila MM, Piltonen T, Puukka K, Ruokonen A, Järvelin MR, Tapanainen JS, et al. Weight Gain and Dyslipidemia in Early Adulthood Associate with Polycystic Ovary Syndrome: Prospective Cohort Study. J Clin Endocrinol Metab. 2016;101(2):739-47.

Demir I, Guler A, Alarslan P, Isil AM, Ucman O, Aslanipour B, et al. Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome. Endocrine. 2019;65:175-83.